What's Next? Trends and Opportunities in the Italian Pharmaceutical Industry.

Trends and Opportunities in the Italian Pharmaceutical Industry: An Overview of the Market for the 2021–2026 Period.

Market Analysis

The Italian pharmaceutical market has performed poorly in recent years, recording steady growth in 2017, followed by a decline in 2019.

In 2021, the Italian pharmaceutical sector grew by 0.8%, showing a negative trend and weak growth due to the impact of the COVID-19 pandemic. The market grew in 2022, and slow growth is projected through 2025.

Unlike many other businesses and industries worldwide that suffered severe disruptions due to the COVID-19 pandemic, the pharmaceutical market performed relatively well. Although nationwide lockdowns and border restrictions caused some supply chain issues, most companies maintain significant inventories to cope with such situations. Furthermore, some of the leading pharmaceutical companies have received substantial public and private investments to support the development of vaccines capable of protecting against the virus and controlling its spread, which has likely offset the losses caused by supply chain disruptions. This means that the COVID-19 pandemic has had a relatively minimal impact on the Italian pharmaceutical market.

Italy holds a 7.8% share of the European pharmaceutical market and was the fourth-largest market in Europe in 2021.

The market is projected to grow at a CAGR of 0.9% from 2021 to 2026, which should bring the market to a value of $27.6 billion by the end of 2026. By comparison, the French and German markets will grow at CAGRs of 3% and 5.1%, respectively, over the same period, reaching values of $84.3 billion and $102.7 billion in 2026.

The market has been driven in part by Italy’s aging population and the rise in age-related diseases, such as diabetes and cardiovascular diseases. Italy has one of the oldest populations in the world, with an average age of approximately 47.2 years. Nearly 48% of the population is aged 18 to 69 and older, of which 32.8% is over 64 years old. This trend will continue to drive demand for pharmaceutical products over the long term, which could help the market withstand a further decline.

…